Penny Stock on Focus: Genetic Technologies Limited (GENE)

Company Profile:

Genetic Technologies Limited is a molecular diagnostics company. The Company offers predictive testing and assessment tools to help physicians manage women’s health. The Company’s lead product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The Company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/gynecologists (OBGYNs) and breast cancer risk assessment specialists, such as breast surgeons. The Company operates in Australia, the United States and Switzerland. The Company’s subsidiaries include Genetic Technologies Corporation Pty. Ltd. and Phenogen Sciences Inc. The Company has launched the BREVAGen test across the United States through its subsidiary, Phenogen Sciences Inc. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.

Recent News:

On Jun 22, 2016, Genetic Technologies Limited announced an update on its marketing partnership with Verizon IndyCar Series driver, Pippa Mann. The program commenced with the Indianapolis 500, the largest single day sporting event in the world, in terms of on-site attendance.

On Jun 21, 2016, the company announced the appointment of Dr. Susan J. Gross, MD, FRCSC, FACOG, FACMG as Senior Medical Director, effective 20 June 2016.

On Dec 21, 2015, the company announced the publication of a new independent study in support of the BREVAGenplus® breast cancer risk assessment test for Caucasian women.

Fundamental Analysis:

Ninestocks analyzes several different financial aspects: Growth, Profitability, solvency and efficiency.

Growth – Measures the growth of both the company’s income statement and cash flow.


Profitability – Measures the historical price movement of the stock.


Solvency – Measures the solvency of the company based on several ratios.


Efficiency – Measures the strength and historic growth of a company’s return on invested capital.



GENE’s strengths can be seen in its better efficiency compared with its peers. Technical indicators signal the bullish signs, as there is a bullish cross in MACD and Stochastic Oscillator. RSI is increasing to 55.39. We rate the Owens & Minor Inc. (OMI) a STRONG BUY.

About the Author

has written 15158 stories on this site.

Write a Comment

Gravatars are small images that can show your personality. You can get your gravatar for free today!

You must be logged in to post a comment.

Copyright © 2012 Nine Stocks